Introduction: Thymic epithelial tumors (TETs) are rare intrathoracic malignancies for which surgery represents the mainstay of the treatment. Current practice for postoperative radiotherapy (PORT) is highly variable, and there is a lack of prospective, high level evidence. Réseau Tumeurs Thymiques et Cancer (RYTHMIC) is the nationwide network for TETs in France. Established in 2012, it prospectively collects data on all TET patients, for whom management is discussed at a national multidisciplinary tumor board (MTB). We assessed whether PORT decisions at the MTB were in accordance with RYTHMIC guidelines and ultimately implemented in patients.
analyzed. The decision of the MTB was in accordance with guidelines in 221 patients (92%) of the 241 with stage I or III TET. An MTB decision to deliver PORT was made for 117 patients (43%). PORT was ultimately initiated in 101 patients. The most frequent reason for not delivering PORT was excessive (>3 months) delay after surgery. Dosevolume constraints defined by the International Thymic Malignancy Interest Group were followed in all but four patients.
Conclusion:
Our data provide a unique insight into the decision-making process for PORT in TETs, highlighting the need for systematic discussion at an expert MTB, while stressing the value of current available guidelines.
Introduction
Thymic epithelial tumors (TETs) are rare intrathoracic malignancies that may be aggressive and difficult to treat. 1, 2 TETs are classified according to the WHO histopathologic classification, which distinguishes thymomas from thymic carcinomas. 1 Thymomas are further divided into five subtypes (A, AB, B1, B2, and B3) on the basis of the morphologic features of the epithelial tumor cells, the relative proportion of the nontumoral lymphocytic component, and the resemblance to normal thymic architecture. 3 TETs are historically staged according to the Masaoka-Koga staging system, 4 which is being replaced by the eighth edition of the TNM staging classification 5 after an analysis of the International Thymic Malignancy Interest Group (ITMIG) retrospective database of more than 10,000 cases that was performed with the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee. 6 Surgery represents the mainstay of the treatment strategy. Preoperative chemotherapy may be proposed when complete resection is deemed to not be achievable upfront. 1, 2 Recurrence rates after surgery range from 10% in Masaoka-Koga stage I or II thymomas to 30% in stage III thymomas and stage I or II thymic carcinomas and 60% in stage IV thymoma and stage III thymic carcinomas. 7 Although a large number of recurrences actually occur in the pleura, 8 postoperative radiotherapy (PORT) to the anterior mediastinal postoperative bed has historically been the standard of care. 2, 9 Recent reports from large databases, [10] [11] [12] [13] [14] [15] [16] [17] as well as pooled analyses of retrospective studies, 15 indicated (1) the absence of a survival benefit after radiotherapy in stage I thymoma, and a debatable survival benefit after R0 resection of stage II or III thymoma [10] [11] [12] [13] 16, 17 ; (2) a similar rate of recurrence whether or not patients received PORT after complete resection of thymoma 15 ; and (3) a recurrencefree and overall survival benefit after resection of thymic carcinoma. 11, 13, 14, 17 As no randomized or even prospective study has been conducted to assess the effect of PORT on recurrence rate or survival, available guidelines are of low levels of evidence. 2, 9 Réseau Tumeurs Thymiques et Cancer (RYTHMIC) is the nationwide network for TETs in France, which was established in 2012. 18 RYTHMIC prospectively collects data for all TET patients, for whom management is systematically discussed on a real-time basis at a national multidisciplinary tumor board (MTB). Decisions are based on national recommendations, as well as on those from the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines. 2 In this study, we assessed whether PORT decisions at the MTB were in accordance with ESMO/RYTHMIC guidelines and ultimately implemented in patients; we also verified how ITMIG definitions and recommendations for dose-volume constraints were actually followed in a real practice setting.
Material and Methods

Study Design
RYTHMIC is dedicated to the management of TETs. It was appointed in 2012 by the French National Cancer Institute as part of a rare cancer program. 18 The network aims at nationwide coverage by 14 regional expert centers, dissemination of the highest standards for diagnosis and treatment, and promotion of collaborative research. The RYTHMIC MTB meets twice a month using a web-based conferencing system, and patients' characteristics, treatments, and follow-up are prospectively collected in the network database. MTB decisions are based on RYTHMIC recommendations (downloadable at www.rythmic.org/01/images/RYTHMIC/Doc/Referentiel_ RYTHMIC_2016.pdf), which are based on the ESMO clinical practice guidelines. 2 According to the ESMO/RYTHMIC guidelines, PORT is not indicated after complete resection of Masaoka-Koga stage I thymoma; PORT is considered for stage II thymoma in cases of aggressive histologic type (type B2 and B3) or extensive transcapsular invasion (stage IIB). PORT is recommended after complete resection of stage III or IVA thymoma. For completely resected thymic carcinomas, PORT is optional for stage I tumors and recommended for stage II to IVA tumors. PORT is also recommended in cases of incomplete resection.
Registration of all patients in whom a TET has been diagnosed is recommended as a part of good clinical practice for oncologists. From January 2012 to January 2015, a total of 828 patients were enrolled. According to national epidemiological data, the RYTHMIC network is estimated to cover 95% of newly diagnosed cases in France. The current analysis was approved by the steering and ethics committee of the RYTHMIC network.
Identification of Patients
Inclusion criteria for this analysis were as follows: (1) histologically confirmed TET, (2) surgical resection of the tumor, and (3) discussion at the RYTHMIC MTB about whether PORT should be delivered. The inclusion period was from January 2012 to January 2015.
Data Collection
The data (including patients' baseline characteristics, histologic type, stage, surgery data, and decision for PORT by the MTB) were collected from the RYTHMIC database and completed by a review of patients' medical records, especially for further analysis of radiation techniques. Radiation data, based on the ITMIG standard definitions and recommendations for dose constraints, 19 were collected by contacting the radiation oncologist in charge of the patient within the network.
Masaoka-Koga stage was assessed according to the ITMIG recommendations by using clinical, imaging, and pathological findings.
4 Lymph node status was specified as no involvement (N0), involvement of anterior or perithymic nodes (N1), or involvement of deep intrathoracic or cervical nodes (N2). Surgical resection was classified as complete (R0), microscopically incomplete (R1), or macroscopically incomplete (R2).
Tumor stage was also classified according to the eighth edition of the American Joint Committee on Cancer/Union for International Cancer Control TNM system. 5 
Statistical Analyses
All patients were included in the statistical calculations. Categorical variables were compared by using the chi-square test and continuous variables were compared by the Mann-Whitney nonparametric test. The differences were considered statistically significant at the 0.05 level (bilateral test). All analyses were performed using SPSS software, version 23.0(SPSS, Inc., Chicago, IL).
Results
Patients' Characteristics
PORT was discussed at the RYTHMIC MTB for 274 consecutive patients during the study period ( Table 1) . The median age at diagnosis was 60 years (range 17-90). The TET histologic type was thymoma in 243 patients (89%) and thymic carcinoma in 31 patients (11%). Complete resection (R0) was achieved in 222 patients (81%). Overall, 241 tumors (88%) were Masaoka-Koga stage I to III and 33 (12%) were stage IVa or IVb (Table 1 and Fig. 1 ). Applying the eighth edition of the TNM system, 15 Masaoka-Koga stage III were reclassified to stage I or II ( Supplementary Fig. 1 ). Type B3 thymoma and thymic carcinoma were more frequently diagnosed as stage III or IV, whatever staging system was used (p < 0.001).
Preoperative chemotherapy was delivered to 17 patients with stage III or IV TET (cisplatin-doxorubicin [Adriamycin, Pfizer, New York, NY]-cyclophosphamide in 13 cases; cisplatin-etoposide in three cases, and vindesine-ifosfamide-cisplatin in one case).
Decision for PORT at the RYTHMIC MTB
The decision to deliver PORT was made by the RYTHMIC MTB for 117 patients (43%), including 91 patients with stage I to III TET and 26 patients with stage IV TET (see Table 1 and Supplementary Fig. 1 ). The decision to not deliver PORT was made for 157 patients (57%). The following characteristics were significantly associated with the decision to deliver PORT: thymic carcinoma (p < 0.001) and type B3 thymoma (p < 0.001) versus other subtypes, higher Masaoka-Koga (p < 0.001) and eighth edition TNM stages (p < 0.001) versus lower stages (see Table 1 and Fig. 1 ), and incomplete resection versus complete resection (p < 0.001) (see Table 1 ). The decision to deliver PORT to the three patients with Masaoka-Koga stage I TETs was based on R1 resection for two cases and the thymic carcinoma histologic type for one case.
Given the switch of some Masaoka-Koga stage II and III tumors to eighth edition TNM stage I and the switch of some stage III tumors to eighth edition TNM stage II tumors, the percentage of stage I tumors for which the decision to deliver PORT was made increased significantly, from 4% to 27%, when tumors were restaged from the Masaoka-Koga system to the eighth edition TNM system (Fig. 2) .
Concordance between MTB PORT Decisions and Guidelines
As no recommendation about PORT is available for stage IV TETs in the ESMO/RYTHMIC guidelines, our assessment of the concordance between guidelines and MTB decisions was limited to the 241 patients with stage I to III TETs (see Fig. 1 ). The MTB decision was in accordance with ESMO/RYTHMIC guidelines for 221 patients (92%) ( Table 2) : 84 patients for whom PORT was recommended by the guidelines and decided on at the MTB (Fig. 3) and 137 patients for whom PORT was not decided on and not indicated.
The decision about PORT made at the RYTHMIC MTB was not in accordance with the ESMO/RYTHMIC guidelines for 20 patients with stage I to III TETs; those decisions consisted of the MTB decision of no PORT when guidelines would have recommended PORT for 13 patients in the setting of poor general condition (n ¼ 10), carcinoid histologic subtype (n ¼ 2), and discordance in staging (n ¼ 1) and the MTB decision in favor of PORT when the guidelines would have recommended no PORT in seven patients. This was related to reported intraoperative tumor fragmentation in two of these seven cases, but in the cases of the other five patients who received PORT, a clear explanation for inconsistency with the guidelines was not found. However, those cases-two patients with type B2, stage IIA thymomas and three patients with type AB, stage IIB thymomasactually corresponded to those in the "gray zone" of guidelines.
The ESMO/RYTHMIC guidelines for PORT are largely based on Masaoka-Koga stage. Implementation of the eighth edition TNM stage leads to an algorithm for PORT that is driven mostly by histologic type ( Supplementary   Fig. 2 ). When compared with Masaoka-Koga stage, PORT was more frequently indicated in eighth edition TNM stage I (27% versus 4% in Masaoka-Koga staging) and II (90% versus 77% in Masaoka-Koga staging).
Implementation of MTB Proposal
In the 117 patients for whom the decision to deliver PORT was made at the RYTHMIC MTB, PORT was actually initiated in only 101 patients; the reported explanations for not initiating PORT in 15 patients were as follows: more than 3 months' delay since surgery (n ¼ 8) (which is the maximal delay for starting PORT according to expert recommendations 2, 19 ), postoperative morbidity (n ¼ 4), poor medical condition (n ¼ 2), and concurrent malignancy (n ¼ 1). In addition, five patients did not complete PORT because of poor medical condition and comorbidities.
PORT was administered in 54 different radiation therapy centers. The median delay between surgery and initiation of PORT was 71 days (range 31-105 days). 
PORT Modalities and Quality Criteria
Overall, 96 patients completed PORT, which was delivered using a conformal three-dimensional technique for 29 patients and intensity-modulated radiation therapy for 67 patients. The total dose was variable depending on completion of resection; the median total dose was 50 Gy after R0 resection and 56 Gy after R1/2 resection (p < 0.001) (Supplementary Fig. 3 ).
The quality criteria based on dosimetric constraints listed in the ITMIG standard definitions guidelines were followed in all but four patients (4%) ( Table 3) .
Discussion
Taking advantage of the RYTHMIC network infrastructure, our analysis is to the best of our knowledge, the first study to assess the decision making for PORT in TET. In the unique setting of systematic prospective discussion at an expert MTB of all patients for whom PORT may be considered, our results support the clinical relevance of the available guidelines based on MasaokaKoga staging and stress the potential issues when switching to the eighth edition of the TNM system. Meanwhile, our data highlight some challenges regarding the actual implementation of the MTB decision, the optimal total dose, and the need for strict quality assurance.
Our study is, we believe, the first to report on a large cohort of consecutive patients with resected TETs, for whom the decision for PORT was systematically and prospectively made at an expert MTB on the basis of consensual guidelines, 2 ensuring a better understanding of PORT or no-PORT decisions. The ESMO guidelines are actually based on survival or recurrence results from large retrospective series, in which such information was not made available. [10] [11] [12] [13] [14] [15] [16] [17] In those series, similar to what is observed in our cohort (Table 1) , patients who received PORT were more likely to have incomplete resection or higher-stage or higher-histological grade tumors, but the exact driver of the decision remained unknown; therefore, the reported absence of differences in terms of recurrence or survival rates after PORT or no PORT 12, 15, 17 may even suggest a role of PORT in reducing or overcoming the risk for recurrence in patients with poor outcome. This may explain the conflicting results of PORT, especially after complete resection of invasive, stage II or III TETs, with some series reporting on the absence of recurrence-free or overall survival benefit 12, 15, 17 and other series showing a significant survival benefit. 10, 11, 14, 16 One limitation of our analysis is the absence of a sufficient follow-up to report on recurrence and survival rates. Also, we did not analyze radiation treatment plans in depth to precisely check that actually treated areas were delineated with accurate margins (according to preoperative and postoperative imaging). Ultimately, our data indicate that the ESMO guidelines algorithm for PORT are relevant in routine practice, with the major drivers of decision being histologic type, completeness of resection, stage, and possibly histologic subtypes for thymomas 2 ; our cohort clearly fit within this algorithm (see Fig. 1 ).
The eighth edition of the TNM staging classification is now being implemented in the clinic. 5 In this staging system, all Masaoka stage I and II and some stage III TETs are merged with stage I tumors on the basis of their similar prognosis in the ITMIG/International Association for the Study of Lung Cancer retrospective database, which may have actually been influenced by the delivery of PORT.
6,7 TNM stage II tumors are defined by pericardium invasion, and TNM stage III tumors are further subdivided into two groups (T3 and T4), aiming at providing more help in formalizing whether the tumor may be considered resectable, which is a major driver of the treatment strategy in advanced TETs. With regard to PORT, one major issue is how those Masaoka stage II and III tumors that are currently eligible for PORT will be identified among the eighth edition TNM stage I tumors; histologic type-and subtype for thymomas-becomes the prominent driver, as shown by the breakdown of patients of our cohort in an algorithm integrating eighth edition TNM stage (see Supplementary Fig. 2 ). In our study, recommendations for PORT were associated with type B3 thymoma histologic subtype, which may be related to (1) the well-established correlation between histologic type and Masaoka-Koga stage, with stage III and IV tumors being more frequently diagnosed with type B3 and carcinoma histologic type, 3 and (2) the fact that ESMO/RYTHMIC recommendations integrate histologic subtype for thymoma into the decision algorithm for PORT in the case of stage II tumors. 2 Interestingly, in a recent analysis of the National Cancer Database, thymic carcinoma and type A and AB thymomas were associated with an overall survival benefit for PORT, whereas types B1, B2, and B3 were not. 20 Until more data are available, one recommendation of the ESMO Clinical Practice Guidelines is to keep the Masaoka-Koga system for PORT decision making.
2 Ultimately, pragmatism and good clinical sense is key in the setting of a rare tumor with a limited amount of highlevel evidence in the literature, especially for MasaokaKoga stage II TETs. In our series, more than 50% of decisions made at the MTB that were not in accordance with the guidelines consisted of not recommending PORT when the guidelines would have; these decisions were primarily related to the clinical status of patients after surgery. Meanwhile, PORT was delivered to selected patients with stage IV TETs, mostly consisting of TETs associated with mediastinal lymph node metastases. The variety of clinical situations stresses the value of personalizing the decision making for PORT, even if guidelines are followed for a majority of patients.
The RYTHMIC model of systematic discussion of all patients with TETs at the MTB while patients remain treated locally or regionally at designated expert centers faces some challenges. Although PORT was decided on at the MTB for 117 of the 274 patients in our cohort, only 101 patients (86%) began receiving PORT and 96 (82%) completed it. Although the implementation rates are high, assessment of performance status and postoperative morbidity may be difficult when discussing numerous cases at the web conferencing-based MTB. Systematic discussion at the MTB, together with administration of PORT in 54 different radiation therapy centers, in accordance with French health care system processes recommending that patients be treated at the facility closest to their home, may explain the delay of 71 days between surgery and initiation of PORT, which was longer than expected, as well as some heterogeneity of practices regarding total dose (which is a major point of discussion among experts and in the guidelines, as limited levels of evidence are available in the literature 2, 19 ) and quality assurance criteria regarding dosimetric constraints. 19 The ESMO guidelines recommend that PORT be started within 3 months after the surgical procedure on the basis of expert consensus. 2 We found a median delay of 71 days between surgical procedure and PORT, which may be related not only to postoperative morbidity, time to finalize pathological reporting, and delays for organizing the patient pathway to and within radiation oncology facilities but also possibly to the RYTHMIC workflow itself. The RYTHMIC MTB is held twice a month, which may not be sufficient to ensure rapid decision making about PORT. Also, reporting to treating physicians about the MTB decision may be quicker. Finally, we plan to optimize the identification of patients operated for a thymic tumor, reduce those delays, and have an earlier discussion at the MTB.
Finally, although a prospective central review of radiation treatment plans for PORT do not seem feasible, the dissemination of guidelines regarding dosimetric constraints seems mandatory within the RYTHMIC network to avoid the unacceptably high parameters observed for some patients in our study.
Ultimately, clinical trials assessing PORT for TET are currently being conducted in the People's Republic of China and enrolling patients with stage II or III completely resected thymomas (ClinicalTrials.gov identifiers NCT02014805 and NCT02633553). The results of these trials will provide a high level of evidence regarding recurrences in and out of the radiation field and survival rates, provided a sufficient follow-up of patients is performed. To conclude, our data provide unique insight into the decision-making process for PORT in TETs, highlighting the need for a systematic discussion at an expert MTB while stressing the value of current available guidelines.
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